NCT07187479View on ClinicalTrials.gov

Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus

NARecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 14, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Chronic Kidney Disease (Stages 4 and 5)Kidney DiseaseType 2 Diabetes
Interventions
OTHER

Physiologic Insulin Resensitization (PIR)

PIR is a physician-directed treatment that uses an exterior infusion pump to deliver insulin intravenously.

Trial Locations (1)

85027

RECRUITING

Arizona Kidney Disease and Hypertension Center, Phoenix

All Listed Sponsors
lead

Well Cell Global

INDUSTRY